BLAINTRAVENOUSINJECTABLEPriority Review
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
SPEVIGO (spesolimab-sbzo) by Boehringer Ingelheim is interleukin-36 receptor antagonists [moa]. First approved in 2022.
Drug data last refreshed 33m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPEVIGO (spesolimab-sbzo) is an intravenous interleukin-36 receptor antagonist approved by the FDA in September 2022. It is a first-in-class biologic designed to treat generalized pustular psoriasis (GPP) and other IL-36-mediated inflammatory conditions. The drug works by blocking IL-36 signaling, a key inflammatory pathway in severe pustular skin disease.
$0.002BPart D
PeakEarly commercial phase in a rare disease niche with modest but growing adoption; team size likely small to mid-sized specialized unit within Boehringer Ingelheim dermatology.
Mechanism of Action
Interleukin-36 Receptor Antagonists
Pharmacologic Class:
Interleukin-36 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SPEVIGO represents a niche opportunity in rare disease dermatology within a large pharma structure; roles are highly specialized with focus on physician engagement, patient identification, and payer education in a small, defined patient population. Career progression may be faster in a high-touch rare disease environment, but total team size and revenue scale are modest compared to blockbuster franchises.
Brand Manager
Worked on SPEVIGO at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.